secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2021-11-26T23:59:59+00:00
Accession:  0001654954-21-012629
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma fails Nasdaq independent director rule; cure until Nov 2022
------------------------------------------------------------------------

- Received Nasdaq notice on Nov 23, 2021 for non-compliance with Listing Rule 5605 after appointing Michael Breen as Executive Chairman.
- Breen resigned from Audit, Compensation, and Nominating Committees on Nov 23, 2021, triggering the deficiency.
- Cure period runs until earlier of next annual shareholders' meeting or Nov 8, 2022 (or May 9, 2022 if meeting before).
- Company is reviewing independent director candidates and expects to regain compliance within the cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000165495421012629/0001654954-21-012629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000165495421012629/gtbp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-21-012629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer